SuppreMol GmbH : SuppreMol appoints industry expert Klaus Schollmeier as CEO

 SuppreMol GmbH : SuppreMol appoints industry expert Klaus Schollmeier as CEO

SuppreMol GmbH / SuppreMol appoints industry expert Klaus Schollmeier as CEO .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

Munich,  Germany,  April   02,  2013:   SuppreMol  GmbH,   a  privately   held 
biopharmaceutical company  developing novel  therapies  for the  treatment  of 
autoimmune diseases, today announced the appointment of Dr. Klaus  Schollmeier 
as Chief Executive Officer (CEO) of  the Company with effect April 1st,  2013. 
Dr. Schollmeier succeeds  Prof. Dr. Peter  Buckel, who resigns  as CEO  having 
reached retirement age.

Dr. Schollmeier has more than 25 years of successful international  management 
experience in the pharmaceutical and biotech industry as well as in investment
banking. Dr.  Schollmeier led  Santhera Pharmaceuticals  AG as  CEO since  the 
company's foundation in 2004 and acts  as Chairman of the Board since  October 
2011. Previously, he was Managing  Director Healthcare / Biotechnology at  ING 
BHF-Bank. Before this,  he spent 16  years in the  pharmaceutical industry  at 
BASF, Knoll  and  Abbott. His  scientific  responsibilities included  head  of 
oncology/immunology research at  BASF's central laboratories  in Germany,  and 
senior director of biotechnology at BASF Bioresearch Corporation in Cambridge,
US. His business functions included General Manager of BASF Pharma Netherlands
and Vice President  and General  Manager for Western  Europe. Mr.  Schollmeier 
holds a Ph.D. in Biology from the University of Düsseldorf, Germany.

Dr. Thomas Hecht, Chairman of the Advisory Board of SuppreMol GmbH, said:  "We 
are very pleased to have  Dr. Schollmeier joining our  Company at a time  when 
SuppreMol is  entering  a new  and  exciting phase.  The  Company has  a  very 
promising product candidate for the treatment of autoimmune diseases in  phase 
II clinical  development with  important  clinical and  regulatory  milestones 
ahead. Dr. Schollmeier will bring the  necessary experience to the Company  to 
advance SuppreMol's products towards  a BLA (Biologics License  Application)." 
Dr. Hecht added: "On behalf of the Board I would like to thank Prof. Dr. Peter
Buckel for his long-standing  commitment to the success  of SuppreMol and  his 
valuable contributions in building the company over the past years."

"I  look  forward  to  leading  SuppreMol  in  the  exciting  years  to  come. 
SuppreMol's product candidates are based on innovative science and have  shown 
promising data in early  clinical trials," stated  Dr. Klaus Schollmeier,  the 
Chief Executive Officer  of SuppreMol  GmbH. "I  will lead  the corporate  and 
commercial development of SuppreMol in the years to come with the ambition  to 
successfully advance the key assets, in particular the lead program SM101."

About SuppreMol
SuppreMol GmbH is a privately held biopharmaceutical company developing  novel 
therapeutics for  the  treatment  of autoimmune  and  allergic  diseases.  The 
company is pioneering the development  of soluble Fc-gamma receptors  (FcgRs), 
which  are  recombinant  autologous  therapeutic  proteins  with  a   specific 
immunoregulatory potential. The  company's lead product  SM101, a  recombinant 
soluble FcgRIIB  is in  phase II  clinical development  for the  treatment  of 
Primary Immune Thrombocytopenia (ITP)  and Systemic Lupus Erythematosus  (SLE) 
and has  potential to  treat Rheumatoid  Arthritis (RA)  and other  autoimmune 
conditions.  SuppreMol's  pipeline  also  includes  two  antibody  development 
programs utilizing the inhibitory effect  of FcgRIIB suitable for  alternative 
treatment strategies and indications as well as an anti-IL-3 antibody to treat
RA. SuppreMol  was founded  as a  spin-off from  the laboratory  of Prof.  Dr. 
Robert Huber,  Nobel Prize  Laureate  in Chemistry  1988,  at the  Max  Planck 
Institute for  Biochemistry in  Martinsried, Germany.  To date  SuppreMol  has 
raised € 40.3  million through  private investors. Major  shareholders in  the 
company include  MIG Fonds,  BioMedPartners  AG, Santo  Holding GmbH  and  FCP 
Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max
Planck Society, and Z-Cube.

Contact

SuppreMol GmbH

Dr. Klaus Schollmeier
Chief Executive Officer

Tel: +49 89 30 90 50 680
E-mail: info@suppremol.com
www.suppremol.com

Press Release PDF

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: SuppreMol GmbH via Thomson Reuters ONE
HUG#1689453

--- End of Message ---

SuppreMol GmbH
Am Klopferspitz 19 Martinsried/Munich Germany
 
Press spacebar to pause and continue. Press esc to stop.